• Blog
  • Non Hodgkin Lymphoma (NHL) Market Report

    Non Hodgkin Lymphoma (NHL) Market Report

    Non Hodgkin Lymphoma (NHL) Market Report
    Report code - SR1430 Delivery - 2 Weeks
    Get Free Sample |
    Non-Hodgkin Lymphoma (NHL) Market Trends, Dynamics & Market Insights
    See more...

    Impact of COVID-19 on Non Hodgkin Lymphoma (NHL) Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Non Hodgkin Lymphoma (NHL) Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Non-Hodgkin Lymphoma (NHL) market is projected to grow from USD 8.1 billion in 2020 to USD 12.4 billion by 2026 at a CAGR of around 7.4% during the forecast period.

    Figure: Non-Hodgkin Lymphoma (NHL) Market Size, 2020-2026 (USD Billion)

    Non-Hodgkin-Lymphoma-Market-Forecast

    Wish to get a free sample? Register Here

    What is non-hodgkin lymphoma?

    Non-Hodgkin lymphoma also referred to as non-Hodgkin's lymphoma, NHL, or lymphoma is a type of cancer that starts in white blood cells called lymphocytes, a part of the body’s immune system. The various types of drugs used to treat Non-Hodgkin lymphoma include monoclonal antibodies, antibody-drug conjugates, btk/bcl-2 kinase inhibitors, pi3 kinase inhibitors, protease inhibitors, and others.

    Key Players

    Key players operating in the Non-Hodgkin Lymphoma (NHL) market are-

    • F. Hoffmann-La Roche AG (Switzerland)
    • Johnson & Johnson (US)
    • The Merck Group (Germany)
    • Bristol Myers Squibb (US)
    • Celgene Corporation (US)
    • Eli Lilly and Company (US)
    • GlaxoSmithKline plc (UK)
    • Bayer AG (Germany)
    • AstraZeneca plc (UK)
    • The Takeda Pharmaceutical Company Limited (Japan).

    Market Dynamics

    The growth of the non-Hodgkin lymphoma (NHL) market is primarily driven by increasing incidences of lymphoma cancer disease across geographies. Changing lifestyles and unhealthy diets are some of the factors resulting in cancer disease, which is likely to drive the market growth at a significant rate during the review period. In addition to this, surging demand for new cancer treatment drugs is likely to create lucrative opportunities for the players operating in the global market in the coming years.

    Segments' Analysis

    Type Trends

    By type, the non-Hodgkin lymphoma (NHL) market has been bifurcated into hospitals and clinics. Under these, the hospital segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment growth can be attributed to the presence of established infrastructure and skilled healthcare staff.

    Regional Trends

    By region, the market in North America accounted for the largest market share in 2020 and is projected to grow at a significant CAGR during the assessment period. The segment growth is primarily attributed to the rising number of people suffering from lymphoma cancer coupled with the presence of key market players such as Bristol Myers Squibb (US) and Celgene Corporation (US). The market growth in the Asia-Pacific region is expected to be driven by the increasing prevalence of cancer disease.

    COVID-19 Impact on Non-Hodgkin Lymphoma (NHL) Market

    The outbreak of the COVID-19 virus has affected the growth of the healthcare industry significantly. Stringent lockdown measures and restricted movement of people affected the number of visits to the hospital for cancer treatment due to high focus on treating covid-19 patients and fear of infection.

    Critical Questions Answered in the Report

    • What are the key trends in the Non-Hodgkin Lymphoma (NHL) market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the Non-Hodgkin Lymphoma (NHL) market?
    • What are the key strategies adopted by the major vendors to lead in the Non-Hodgkin Lymphoma (NHL) market?
    • What is the market share of the top vendors?

    Get the full scope of the report. Register Here

    Target Audience

    Here is the list of the group of customers that the non-hodgkin lymphoma market hopes to have the greatest opportunity to convert-

    • Non-Hodgkin lymphoma (NHL) distributors
    • Non-Hodgkin lymphoma (NHL) suppliers
    • Non-Hodgkin lymphoma (NHL) manufacturers
    • Logistics organizations
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    The non-Hodgkin lymphoma market is expected to witness an impressive growth of 7.4% CAGR in the coming years.

    F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (US), The Merck Group (Germany), Bristol Myers Squibb (US), Celgene Corporation (US), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Bayer AG (Germany), AstraZeneca plc (UK) and The Takeda Pharmaceutical Company Limited (Japan) are among the key players in the non-Hodgkin lymphoma market.

    The non-Hodgkin lymphoma market size is expected to reach USD 12.4 billion in the foreseeable future.

    The hospital segment is expected to register significant growth in the non-Hodgkin lymphoma market in the coming years.

    North America accounted for the largest share in the non-Hodgkin lymphoma market in the next five years.

    Non-Hodgkin lymphoma (NHL) distributors, Non-Hodgkin lymphoma (NHL) suppliers, Non-Hodgkin lymphoma (NHL) manufacturers, Logistics organizations, Government bodies are the target audience in the non-Hodgkin lymphoma market.

    //